SpaceX’s IPO demand outstripped supply by more than four times. The company plans to sell 555.6 million shares at $135 each, trading on Nasdaq under SPCX as early as tomorrow. If it holds, this will be the biggest IPO in U.S. history. Investors clearly bet on Musk’s vision and SpaceX’s cash-flow potential from Starlink and launch services. In the AI world, OpenAI and Anthropic look set for a price battle. OpenAI may slash token rates to match anticipated cuts by Anthropic, as enterprise customers push back on high compute bills. Both firms are hemorrhaging cash on GPU costs, so lower prices risk squeezing already thin margins. This fight will test their business models before either goes public. On biotech and devices, Life Biosciences has begun dosing patients with an experimental gene therapy aimed at reversing age-related vision loss by activating three regeneration genes under an antibiotic-controlled switch. Meanwhile, China’s regulator approved NeuraMatrix’s NEO brain-computer interface for commercial use; the coin-sized device decodes neural signals to let patients control a pneumatic glove. Neuralink’s N1 still runs under research protocols in the U.S., with FDA approval years away. In software and platforms, government sites doubling users by adopting an HTML-first approach highlights the power of simplicity and accessibility. Stack Overflow launched “Stack Overflow for Agents,” an API-driven knowledge exchange that uses multi-agent loops and community trust scores to keep corporate documentation accurate at machine speed. And at Anthropic, CEO Dario Amodei reports to no one but his chief of staff—his sister Daniela handles day-to-day ops—so he can focus on research strategy.